CHICAGO, June 2, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that Phase 1 clinical data from studies of MM-151, MM-141, MM-111 and MM-121 was presented at the 2014 American Society of Cancer Oncology (ASCO) Annual Meeting. Data from these studies support the clinical advancement of Merrimack’s novel antibody therapeutics.
Help employers find you! Check out all the jobs and post your resume.
